Transforming Growth Factor β Activates the Promoter of Cyclin-dependent Kinase Inhibitor p15 INK4B through an Sp1 Consensus Site by Li, J. M. et al.
Transforming Growth Factor b
Activates the Promoter of
Cyclin-dependent Kinase
Inhibitor p15INK4B through
an Sp1 Consensus Site*
(Received for publication, August 16, 1995, and in revised form,
September 18, 1995)
Jian-Ming Li‡, Michael A. Nichols§¶,
Subhashini Chandrasekharan§, Yue Xiong§i**,
and Xiao-Fan Wang‡ ‡‡
From the ‡Department of Pharmacology, Duke
University Medical Center, Durham, North Carolina
27708 and the §Curriculum in Genetics and Molecular
Biology, iDepartment of Biochemistry and Biophysics,
Program in Molecular Biology and Biotechnology,
Lineberger Comprehensive Cancer Center,
University of North Carolina,
Chapel Hill, North Carolina 27599-3280
Transforming growth factor b (TGF-b) causes growth
arrest in the G1 phase in many cell types. One probable
pathway for this growth inhibition is through the TGF-b-
mediated up-regulation of the cyclin-dependent kinase
(CDK) inhibitor p15INK4B, which specifically inhibits the
enzymatic activities of CDK4 and CDK6. An active cyclin
D-CDK4/6 complex is required for pRb phosphorylation to
allow the cell cycle to progress from G1 to S phase. To
study the molecular mechanism of the p15INK4B induction
by TGF-b, we isolated a 780-base pair promoter sequence
of the human p15 gene and inserted this fragment up-
stream of a luciferase reporter gene. When this construct
was transiently transfected into HaCaT cells, luciferase
activity was induced more than 10-fold upon TGF-b treat-
ment, indicating that the induction of p15INK4B expres-
sion by TGF-b is partly exerted at the transcription level.
Promoter deletion analysis revealed that the sequence
from 2110 to 240 relative to the transcription start site is
capable of conferring the 10-fold induction by TGF-b.
Within this region there are three Sp1 consensus sites.
Mutation of one of these sites, GGGGCGGAG, substan-
tially reduced both the induction by TGF-b and the basal
promoter activity, whereas mutations in the other two
Sp1 sites and the spacer sequences had little effect. In
addition, gel mobility shift assay indicates that the tran-
scription factors Sp1 and Sp3 bind to this Sp1 site. Taken
together, these data suggest that a specific Sp1 consensus
site is involved in the mediation of TGF-b induction as
well as the basal promoter activity of the p15 gene and
that Sp1 and Sp3 transcription factors might be involved
in this regulation.
Transforming growth factor bs (TGF-bs)1 represent a large
family of cytokines with diverse activities in the regulation of
cell growth, differentiation, and morphogenesis (1–3). TGF-b
causes growth inhibition of most epithelial, endothelial, fibro-
blast, neuronal, lymphoid, and hematopoietic cell types (3).
TGF-b treatment induces growth arrest in the G1 phase of the
cell cycle, and this effect has been attributed largely to an
inhibition of phosphorylation of the retinoblastoma susceptibil-
ity gene product, pRb (4). Progression through the G1 phase of
the cell cycle requires phosphorylation of pRb by G1 cyclin-de-
pendent kinase (CDK) complexes, particularly the cyclin D-
CDK4 and cyclin D-CDK6 complexes (5). Phosphorylation of
pRb releases transcription factors, including members of the
E2F transcription factor family, required for the G1 to S phase
transition of the cell cycle (6).
Two distinct families of CDK inhibitors, represented by p16
and p21, have been identified recently and shown to be capable
of binding to and inhibiting the activities of various CDK en-
zymes (for a recent review, see Ref. 5). The p16INK4 family of
CDK inhibitors specifically interacts with two closely related
CDK proteins, CDK4 and CDK6, both of which have been
strongly implicated as the physiological pRb kinases. One
member of this family, p15INK4B, was specifically up-regulated
by TGF-b in human keratinocyte HaCaT cells (7). The steady-
state level of p15INK4BmRNA was induced 30-fold upon TGF-b
treatment, implicating p15INK4B as a primary effector of the
TGF-b-mediated cell cycle arrest (7). Previously it was shown
that treatment of HaCaT cells with TGF-b caused rapid tran-
scriptional induction of the p21 gene (also known as cip1/
WAF1/sdi1) through a p53-independent pathway, suggesting
that p21 is also involved in mediating the cell cycle arrest
caused by TGF-b (8).
The signaling pathways downstream of the TGF-b receptor
complex that lead to the inhibition of cell cycle progression are
still poorly understood. Since both CDK inhibitors, p15 and
p21, are up-regulated by TGF-b treatment, they could be coor-
dinately regulated through a similar mechanism. In this study,
we attempt to elucidate the mechanism through which TGF-b
specifically up-regulates the expression of p15INK4B by a de-
tailed analysis of the p15INK4B promoter sequences.
EXPERIMENTAL PROCEDURES
Isolation of p15 Genomic DNA—A human placenta genomic library
cloned in l FIX II (Stratagene, La Jolla, CA) was screened with the
full-length human p16 cDNA (9). Of 1.2 million phage plaques screened,
eight positives were isolated. Two oligonucleotide primers, 59 primer (59
AGGATCCATGGTGATGATGGGCAGCGCCCGC 39) and 39 primer (59
GAAGCTTGGGTAAGAAAATAAAGTCGTTG 39), specific to p15 cDNA
were designed based on the previously published MTS2 genomic se-
quence (10) and used in polymerase chain reaction amplification to
distinguish p15 from p16. Three p15 genomic clones were obtained, and
clone G8 was confirmed by DNA sequencing to correspond to the p15
gene as compared with the p15 cDNA sequence (7, 11). A 1.2-kilobase
pair DNA fragment containing a 440-bp exon 1 and 780-bp sequence
upstream of 59-cDNA was isolated from clone G8 and completely se-
quenced by Sanger’s method (12).
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Plasmid Constructs—The HindIII/SacI, ScaI/SacI, SphI/SacI, SmaI/
SacI, PvuII/SacI, and EcoRI/SacI fragments of clone G8 were inserted
between the SmaI and SacI sites of the pGL2-basic luciferase reporter
plasmid (Promega, Madison, WI) to generate p15P751-luc, p15P463-
luc, p15P165-luc, p15P113-luc, p15P35-luc, and p15P23-luc, respec-
tively. Linker scanning mutants of the p15P113-LS series were made by
site-directed mutagenesis (13), and mutant sequences are indicated in
Fig. 3A. p15P97-luc, p15P69-luc, p15P47-luc, and p15P35-luc were con-
structed by inserting the HindIII/SacI fragment of p15P113-LS1, XbaI/
SacI fragment of the p15P113-LS3, and HindIII/SacI fragment of the
p15P113-LS4 between the SmaI and SacI sites of pGL2-basic luciferase
reporter plasmid. All mutations were verified by restriction enzyme
digestion and DNA sequencing.
Gel Mobility Shift Assay—Complementary oligonucleotides from
268 to 282 on the p15 promoter were annealed and labeled with
[g-32P]ATP by T4 polynucleotide kinase. HaCaT cells were treated with
or without TGF-b for 20 h, and the nuclear extract was prepared
according to Dignam et al. (14). 1 mg of total nuclear protein was
incubated with 0.5 mg of poly(dIzdC) as well as the appropriate oligo-
nucleotide competitors or antisera (as indicated in the figure legend) for
20 min on ice in a 20-ml reaction containing 20 mM Hepes (pH 7.5), 5 mM
MgCl2, 60 mM KCl, 1 mM dithiothreitol, 0.1% Triton X-100, and 6%
glycerol. 0.2 ng of the end-labeled probe (2 3 105 cpm) were then added,
and the incubation was continued for 20 min at 30 °C. The protein-DNA
complexes were resolved on a 4% non-denaturing polyacrylamide gel.
The gel was dried and exposed to x-ray film. Rabbit anti-human Sp1
and Sp3 antibodies were generous gifts from Dr. J. Horowitz.
Luciferase Assays—HaCaT cells were plated onto 6-well plates at a
density of 100,000 cells/well. Cells were grown for 48 h and transfected
with 6 mg of plasmid DNA per well with the DEAE-dextran method as
described elsewhere (8). Human TGF-b1 was added to a concentration
of 100 pM, and luciferase activity was assayed 20 h later as described
(8). For each transfected plasmid, two duplicates were assayed under
the same conditions, and the mean relative light units (RLU) were used
in all the figures.
RESULTS AND DISCUSSION
A 780-bp genomic DNA fragment, which contains sequences
upstream of the previously reported 59-ends of the p15INK4B
cDNA (7, 11), was cloned from a human genomic library. The
59-end of the p15 mRNA was mapped to the adenosine in the
sequence CCCCACTCT as shown in Fig. 3A by S1 nuclease
protection assay (data not shown). Thus, the cloned 780-bp
DNA fragment largely contains the p15 promoter sequence.
The sequence around the initiation site matches the initiator
sequence as defined by Smale and Baltimore (15). No apparent
TATA sequence was found around the 225 to 230 region.
Therefore, the p15 promoter may be defined as a TATA-less/
initiator promoter. The p15 promoter sequences are highly
GC-rich (70% G 1 C from 2200 to 21).
To determine its inducibility by TGF-b, the 750-bp p15 pro-
moter sequence was inserted upstream of a luciferase reporter
gene in the vector pGL2-basic (Fig. 1). When the resultant
construct, p15P751-luc, was transiently transfected into Ha-
CaT cells, a 10–15-fold induction of luciferase activity was
FIG. 1. Deletion analysis of the p15 promoter. Luciferase (Luc) constructs with progressive deletions of the p15 promoter sequences are
shown. The restriction sites used in the construction of these deletion constructs are indicated. The initiator (Inr) sequence is indicated as an open
box, and the transcription initiation site is indicated by an arrow. The deletion constructs were transiently transfected into HaCaT cells and the
RLU measured after cells were treated with or without 100 pM human TGF-b1. Each bar represents the mean RLU of two duplicate experiments
under the same assay condition. The fold inductions by TGF-b treatment are shown to the left of bar graph.
FIG. 2. Deletion analysis of the Sp1 consensus sites on the p15 promoter. p15P113-luc, which contains three Sp1 consensus sites and is
fully inducible by TGF-b, is shown. Luciferase (Luc) constructs with one (p15P97), two (p15P69), and three (p15P47) Sp1 consensus sites deleted
are also shown. These constructs were transiently transfected into HaCaT cells and the luciferase activity assayed as described in the legend of
Fig. 1. Fold induction by TGF-b is indicated. Inr, initiator.
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routinely observed upon TGF-b treatment as measured by RLU
(Fig. 1). Thus, the p15 promoter is capable of being induced by
TGF-b, and the transcription activation is at least partly
responsible for the accumulation of p15 mRNA upon TGF-b
treatment (7).
To identify specific promoter elements that confer the TGF-b
induction, a series of 59 processive promoter deletion constructs
were generated (Fig. 1). These deletion constructs were tran-
siently transfected into HaCaT cells and assayed for luciferase
activities in the absence or presence of TGF-b. Fig. 1 shows
that deletions up to the position of 2110 relative to the initia-
tion site did not change the fold of induction by TGF-b although
the overall promoter activities in the presence of TGF-b
dropped about 3-fold. Deleting sequences from 2110 to 230,
however, abolished TGF-b induction (Fig. 1), indicating that a
TGF-b-responsive element is located in this region.
There are three potential Sp1 binding sites within the2110 to
230 sequences upstream of the transcription initiation site of the
p15 gene. Previously, a GC-rich sequence (GCCTCC) capable of
binding to Sp1 and Sp3 was shown to be responsible for the
induction of p21 gene by TGF-b treatment (30). Interestingly,
this sequence is identical to the first Sp1 consensus site in the
2110 to230 fragment of the p15 promoter. To test the possibility
that this sequence, or the other two Sp1 consensus sites, may be
involved in the mediation of p15 promoter induction by TGF-b,
we generated more 59 promoter deletion constructs to delete
either one (p15P97-luc), two (p15P69-luc), or all three Sp1 con-
sensus sites (p15P47-luc) and assayed for their luciferase activi-
ties in the absence or presence of TGF-b (Fig. 2). Fig. 2 shows that
deletion of the first Sp1 consensus site had little effect on either
the induction fold by TGF-b or the basal promoter activity of the
p15 luciferase construct, whereas deletion up to the second Sp1
consensus site reduced TGF-b induction dramatically from 19-
fold of the wild type promoter to 2.8-fold. Deletion of all three Sp1
consensus sites reduced TGF-b induction only slightly further to
1.5-fold near the background level. These data suggest that the
second Sp1 consensus site is the most critical sequence for either
the induction by TGF-b or the basal promoter activity of the
human p15 promoter.
To confirm the importance of the second Sp1 consensus site
in conferring the transcription inducibility of the p15 promoter
by TGF-b, a series of scanning mutation constructs were made
in the promoter context of p15P113, which contains 113 base
pairs upstream of the transcription initiation site and is fully
capable of being induced by TGF-b (Fig. 3A). The scanning
constructs were transiently transfected into HaCaT cells and
assayed for their luciferase activities in the absence or presence
of TGF-b1. With the exception of p15P113-LS3, all mutants did
not change significantly the fold of induction upon TGF-b treat-
ment or the basal transcription activity (Fig. 3B). Mutant
p15P113-LS3, which contains a mutation in the second Sp1 site
within the 2110 to 230 region, decreased the fold of induction
from 12-fold of the wild type promoter to 4-fold (Fig. 3B). In
addition, the basal promoter activity of p15P113-LS3 was also
reduced significantly, approaching the background level (Fig.
3B). Together with the promoter deletion analysis, these data
suggest that a specific Sp1 consensus site is important for the
mediation of TGF-b induction of the p15 gene as well as its
basal promoter activity.
To identify protein factors interacting with the second Sp1
site, we used DNA sequences from 268 to 282 on the p15
promoter covering the second Sp1 site in the gel mobility shift
assay. As shown in Fig. 4, lane 2, three distinctive protein
complexes (I, II, and III) were observed when this probe was
incubated with nuclear extract prepared from HaCaT cells. All
three complexes are specific to the probe since they were
readily competed by an excess of cold homologous competitor
(Fig. 4, lanes 9 and 10) but were resistant to the competition of
nonspecific oligonucleotides (Fig. 4, lanes 7 and 8). Complex I
was abolished when antibody against the human Sp1 tran-
scription factor was included in the binding reaction and there-
fore represents the complex formed between Sp1 and the sec-
ond Sp1 site on the p15 promoter (Fig. 4, lane 4). Similarly,
complexes II and III represent the complexes formed between
Sp3 and the second Sp1 site on the p15 promoter since both
complexes were abolished when the binding reaction includes
antibody against the transcription factor Sp3 (Fig. 4, lane 6).
Together with the promoter mutation analysis, these data
show that the second Sp1 site within the 2110 to 230 region on
the p15 promoter, which is capable of conferring the TGF-b
inducibility of the p15 promoter, binds to the transcription
factors Sp1 and Sp3.
Sp1 consensus sites are present in numerous gene promoters
including many housekeeping genes and cellular proto-onco-
genes (16–18). The well characterized transcription factor Sp1
binds to its cognate binding site and activates transcription
FIG. 3. Scanning mutation analysis of the p15 promoter. A, scanning mutation constructs, p15P113-LS1 through p15P113-LS6, are shown
with the mutated sequences. Sequences from 2113 to 15 of the wild type promoter, p15P113, are also shown and the three Sp1 consensus sites
underlined. The transcription initiation site is indicated by an arrow. Fold induction by TGF-b treatment as measured in panel B is shown for each
construct. B, the scanning mutants were assayed for luciferase activities as described in the legend of Fig. 1.
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presumably through its interaction with the TBP-associated
factor 110 (TAFII110) (19). Recent studies suggest that Sp1 and
a member of the Sp1 family, Sp3, are involved in the regulation
of many growth-related cellular genes, including c-fos, c-myc,
TGF-b1, and TGF-b3 genes, through a cis-acting element
termed the pRb control element (16, 20–22). A model has been
proposed to postulate that the functional interaction between
pRb and Sp1 in vivo results in the “superactivation” of Sp1-
mediated transcription (16). Here we show that a specific Sp1
consensus site is involved in the mediation of TGF-b induction
of the p15 gene and that the Sp1 and Sp3 proteins could bind to
this specific Sp1 site. The same site is also responsible for the
basal promoter activity. Evidence is accumulating that basal
transcription machinery is also capable of being regulated in
cells, presumably through the action of TBP-associated factors
(TAFs). For example, p53 transcription activation is mediated
by TAFII40 and TAFII60 (23) and the presence of TAFII150 and
TAFII250 stabilized the preinitiation complex assembled on an
initiator-containing promoter while it destabilized the complex
on an initiator-less promoter (24). A temperature-sensitive mu-
tation in TAFII250 has been shown to cause cell cycle arrest
(25, 26). It is possible that some TAFs could relay the cues
received from growth signals and affect the transcription
preinitiation complex assembled on certain growth-related
genes.
A GC-rich sequence in the p21 promoter capable of binding to
the Sp1 and Sp3 proteins was shown to be responsible for the
induction of the p21 gene by TGF-b in HaCaT cells (30). Inter-
estingly, this GC-rich sequence, termed TbRE for TGF-b-re-
sponsive element, was capable of conferring TGF-b inducibility
when inserted into an exogenous promoter (30). Based on these
studies, it is conceivable that the same GC-box binding factor(s)
may be involved in the coordinate regulation of both p15 and
p21 genes. Several proteins capable of binding to those GC-rich
sequences including the Sp1 consensus sites have been identi-
fied. Some of these factors have extensive homologies with Sp1
and thus belong to the Sp1 transcription factor family, such as
Sp2, Sp3 and DSp3 (16), whereas others are entirely different
from Sp1, such as ETF and GC-box binding protein (GCF) (27,
28). Notably, Sp3 and GC-box binding protein have been shown
to bind to the GC-boxes, including Sp1 consensus sites, and
repress transcription from certain genes (27, 29). More exper-
iments are needed to determine if Sp1, its family members, or
other novel GC-box binding proteins are involved in the regu-
lation of p15 and p21 genes by TGF-b. It is possible that the
subtle sequence variations and the optimal spacing between
binding sites for various transcription factors could alter the
balance between the positive and negative transcription regu-
lators and consequently exert a different mode of transcription
regulation.
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FIG. 4. Factors binding to the second Sp1 site on the p15 pro-
moter. Complementary oligonucleotides covering the second Sp1 site
on the p15 promoter were labeled with [g-32P]ATP and used in the gel
mobility shift assay. Three protein-DNA complexes (I, II, and III), as
indicated by arrows, were observed when the probe was incubated with
1 mg of nuclear protein (lane 2). In lanes 3 and 4, preimmune sera or
antibody against human Sp1 were included in the binding reaction,
respectively. In lanes 5 and 6, preimmune sera or antibody against
human Sp3 were included in the binding reaction. In lanes 7 and 8, a
50- or 250-fold excess of nonspecific oligonucleotides was included in the
binding reaction. In lanes 9 and 10, a 50- or 250-fold excess of the
homologous oligonucleotides was included in the binding reaction. Lane
1 is probe alone.
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